Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

Thursday, September 5, 2024 2 min read
Key Takeaway: Ardelyx, Inc. announced its participation in the 2024 Cantor Global Healthcare Conference, scheduled for September 19, 2024. Chief Financial and Operations Officer Justin Renz will engage in a fireside chat during the event at 9:10 A.M. Eastern Time in New York City. Ardelyx has a mission to deliver innovative medicines and currently markets two products in the U.S., with further international distribution agreements in place.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is participating in a significant healthcare conference.
  • The company continues to focus on innovative, first-in-class medicines.
  • It has two commercial products approved in the U.S. market.

Full Press Release Details

WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:10 A.M. Eastern Time in New York City.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

Who will participate in the fireside chat at the conference?

Justin Renz, Chief Financial and Operations Officer, will participate.

When is the 2024 Cantor Global Healthcare Conference?

The conference is set for September 19, 2024, at 9:10 A.M. Eastern Time.

Where can I access the webcast of the Ardelyx panel?

You can access it on Ardelyx's Events and Presentations webpage.

What products does Ardelyx have approved in the U.S.?

Ardelyx has IBSRELA® and XPHOZAH® approved in the United States.

What is tenapanor used for in Japan?

In Japan, tenapanor is marketed as PHOZEVEL® for hyperphosphatemia.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx Cantor Global Healthcare Conference tenapanor biopharmaceuticals IBSRELA
Last updated: Sep 5, 2024